Sign Up for a Free Account
  • Updated 10.15.2021
  • Released 07.06.1999
  • Expires For CME 10.15.2024



Historical note and terminology

Riluzole is a member of the benzothiazole class and is believed to be a glutamate antagonist. Several other glutamate antagonists (such as dextromethorphan and branched-chain amino acids) have been tried previously for the treatment of amyotrophic lateral sclerosis but without any success. Riluzole is the first drug to be approved for the treatment of amyotrophic lateral sclerosis; it received United States Food and Drug Administration approval in 1995 and was launched in several countries in 1996.

This is an article preview.
Start a Free Account
to access the full version.

  • Nearly 3,000 illustrations, including video clips of neurologic disorders.

  • Every article is reviewed by our esteemed Editorial Board for accuracy and currency.

  • Full spectrum of neurology in 1,200 comprehensive articles.

  • Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660



ISSN: 2831-9125